Wounds and Injuries  >>  dilmapimod (SB-681323)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
dilmapimod (SB-681323) / GSK
NCT00390845 / 2006-001072-21: P38 Mitogen-activated Protein (Map) Kinase Inhibitor (SB-681323)Study In Patients With Neuropathic Pain

Completed
2
50
Europe, RoW
SB681323, Placebo
GlaxoSmithKline
Pain, Neuropathic
08/08
08/08
NCT00996840: SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS

Completed
2
77
US
SB-681323 Intravenous 3mg, SB-681323 Intravenous 7.5 mg, SB-681323 Intravenous 7.5mg, SB-681323 Intravenous 10mg, Placebo
GlaxoSmithKline
Lung Injury, Acute
02/13
02/13

Download Options